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Abstract: The synthesis and physicochemical properties of new derivatives of N -benzyl and N -phenyl amides 
o f 2-(3-spirocyclohexanepyrrolidine-2,5-dione) acetic acid, 4-(3-spirocyclohexanepyrrolidine-2,5-dione) 
benzoic acid and 4-(3-spirocyclopentanepyrrolidine-2,5-dione) benzoic acid are described. N -substituted 
amides were prepared by condensing the obtained acids with the corresponding phenyl- or benzylamine 
derivatives in DMF, in the presence o f the N,N-carbonyldiim idazol (CDIM) reagent at room temperature. The 
compounds were evaluated for anticonvulsant activity. The portion coefficients were calculated using the 
Prolog P module o f the Pallas system. The structure of the new amides was confirmed by elemental and spectral 
analyses.
Keywords: N-substituted amides o f 3-spirocycloaIkylpyrrolidine-2,5-dione, spirosuccinimides, lipophilicity, 
anticonvulsant properties
A great number of compounds are synthesized 
every year to determine their anticonvulsant prope­
rties. It is well known that 4 - , 6-heterocycle rings, 
one or two carbonyl groups, as well as an aromatic 
system are required to assess their anticonvulsant 
activity (1,2). Among the compounds investigated 
for anticonvulsant activity, one of the structures is 
an amide fragment. The amide function has been 
found in many new compounds with potent an­
ticonvulsant activity such as ameltolide (3), rufina- 
mide, remacemide, seretolide, harkoserid and cera- 
bersat (4) (Figure 1).
Structure-activity relationships of the desc­
ribed amides have shown that the substitution 
pattern and the kind of substituents in an aromatic 
ring are very important for anticonvulsant activity. 
Methyl groups and fluor atoms in the aromatic ring 
seem to be essential here.
Studies carried out by Scott at al. (5, 6) on 
a group of spiro[4,5] and spiro[4,6] carboxyl acids 
as cyclic analogues of valproic acid demonstrated 
anticonvulsant activity of those compounds. Fur­
ther investigation of a group of spiro succinimides 
(7) as well as crystallographic data (8) showed 
a key role of the cyclic system connected with the 
imide fragment through a spiro carbon atom regar­
ding the influence of compounds of that type on 
anticonvulsant activity.
The lipophilic character was demonstrated in 
many types of drug action. It was found that the 
maximum potency of drugs acting on the central 
nervous system was obtained for congeners with an
optimum lipophilicity close to 2. Lien (9) reported 
that the anticonvulsant activity of different types of 
compounds was correlated with their lipophilicity.
In the present study, we determined clog P 
values for all the obtained amides using the Prolog 
P module of the PALLAS system (10). The cor­
relation between the clog P values o f anticonvul­
sant drugs with amide fragment and our new 
compounds I, IV -X II is presented in Table 5.
In recent years, we have synthesized a great 
number of compounds with anticonvulsant activity 
by changing substituents in position 1 and 3 of the 
pyrrolidine-2,5-dione nucleus. Some of them were 
very effective in anti-M ES and sc. Met tests 
(11-14). These findings and the information given 
in the introduction have prompted us to carry out 
synthesis of new derivatives of 3-spirocycloalkyl- 
pyrrolidine-2,5-dione with an amide fragment se­
parated from the imide nitrogen atom by the 
methylene group [IV -VIIJ or the phenyl ring 
[V III-X II],
1-Carboxy-l-cyclohexaneacetic acid and 1-car- 
boxy-1-cyclopentaneacetic acid, obtained by the 
previously described method (5,12), were used as 
starting materials. 4-(3-spiro-cyclohexanepyrroli- 
dine) benzoic acid [II] and 4-(3-spirocyclopen- 
tanepyrrolidine-2,5-dione) benzoic acid [III] were 
synthesized by El-Talbany et al. (15,16) and also 
used as starting materials. In this study, 2-(3-spiro- 
cyclohexanepyrrolidine-2,5-dione) acetic acid [I], 
4-(3-spirocyclohexanepyrrolidine-2,5-dione) ben­
zoic acid [II] and 4-(3-spirocyclopentane-
383
384 JOLANTA OBN1SKA and ALFRED ZEJC
Figure 1. Chemical structures of potent anticonvulsant compounds with amide function.
pyrrolidine-2,5-dione)-benzoic acid [III] were 
synthesized according to the procedures shown in 
Scheme 1.
The obtained acids [I, II, III] were used to 
synthesize new N -benzy l- or N -phenyl- amides of 
3 -sp irocyclohexanepyrrolid ine-2 ,5-dione-l - a c e ­
tic acid [IV-VIJ, 3-spirocyclohexanepyrrolidi- 
ne-2 ,5-dione-l-(4-carboxy)-benzoic acid [VII-X] 
and 3-spirocyclopentanepyrrolidine-2,5-dione — 1- 
(4-carboxy)-benzoic acid [XI, XII]. The amides 
[IV-XII] were prepared by condensing the above 
acids [I, II, III] with the corresponding amine in 
DMF in the presence of carbonyldiimidazol (CDIM), 
yielding 75-80%  (17) (Scheme 2).
'H  NMR and MS spectra of the synthesized 
compounds were studied.
In the MS spectra, the peaks of molecular ions 
[M++ 1 ] were clearly detectable for compounds IV, 
V III-X II (intensity ranging from 82 to 100%))- For 
compounds V -V II, the peaks of molecular ions 
[M++ l] were within the range of 21-27%  intensity. 
The characteristic ions M+ 93 (100%), 107 (100%), 
124 (100%) and M+ 208 (1-15% ) confirmed the
fragmentation of the amide bond in compounds 
IV -V I. The ion M+ 270 (65-100% ) was charac­
teristic o f compounds V II-X  as a peak resulting 
from the fragmentation of the amide bond. In 
amides XI, XII, the ion M+ 256 (56% and 60%) 
also confirmed the fragmentation of amide bond. 
The other peaks of ions M+ 95 (3-18%  and M + 81 
(12-15% ) confirmed the fragmentation of 3-spiro- 
cyclohexane-pyrrolidine-2,5-dione [IV-X] and 
3-spirocyclopentanepyrrolidine-2,5-dione [XI, XII] 
rings. All the characteristic ions agreed with the 
proposed structures.
The 'H NMR spectra revealed there a few 
characteristic chemical shifts of the investigated 
amides. The chemical shifts of pyrrolidine-2,5 -  
dione protons in all the compounds studied were 
shown as singlets at 8 2.64 ppm and 8 2.75 ppm, 
which were raised upfield by 0.03 ppm and 0.02 
ppm, respectively. The resonance signal of -C H 2 
between the imide nitrogen and the amide bond 
[IV-VI] appeared as a singlet at 8 4.29 ppm. The 
resonance signal o f-C F F  benzyl group appeared as 
a dublet at 8 4.30^1.45 ppm [V, I] and 8 4.57-4.65
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ppm [V III-X II], The signal o f the N -H  proton of 
amide group occurs as a singlet at 8 5.99 ppm [V, 
VIJ and as a triplet at 8 6.33 ppm -S 7.18 ppm for 
am ides IV , V II-X II . The chem ical shifts o f the 
cyclohexane ring were within the range of 
8 1.21-1.96 ppm [IV -X ] and of the cyclopentane 
ring within the range of 8 1.57-2.27 ppm. The 
signals o f arom atic protons for all the com pounds 
occurred as m ultiplets within the range of 8 
6 .85-7 .88 ppm.
EX PER IM EN TA L
Chemistry
Melting points (°C) were left uncorrected. 
'H-NM R spectra were obtained on a Varian Mer­
cury spectrometer working at 300 MHz. Chemical 
shifts were described as parts per million (8 ppm); 
(CH,)4Si (TMS) was used as an internal standard.
No. IV V VI VII VIII IX X XI XII
n 2 2 2 2 2
- c 6h 4
2 2 1 1
X i n ■3
3 ! n X -C H 2 - c 6h 4 - c ,h 4h -C 6H4 - c (>h 4 - c 6h 4
m 0 l 1 0 1 1 1 1 1
R H H 4 -F H 4-F 2-O C H , 4-O C H , H 2-OCH.,
Scheme 2.
Table 1. Experimental data of compounds I—III




















1.27-1.85 (10H, m, cyclohexane), 2.62 (2H, 
s, -C H 2 imide), 4.26 (2H, s, CH2), 12.5 (1H, 
s, COOH)












1.21-1.73 (10H, m, cyclo-hexane), 2.74 
(2H, s, -C H 2 imide), 7.39-7.91 (2H, aro­
mat), 8.00-8.04 (2H, aromat), 13.09 (1H, 
br.s, COOH)












1.64-2.01 (8H, m, cyclo-pentane), 2.79 (2H, 
s, -C H 2 imide), 7.41-7.45 (2H, aromat), 
8.00-8.04 (2H, aromat), 13.10 (1H, br.s, 
COOH)
Solvents: A) chloroform : methanol : acetic acid (60 : 10 : 5) , B) butanol : acetic acid : water ( 5 : 4 :  1) 
b Compound I  in CDCl,








IV C i7H2()0,N2 78 68.06 6.72 9.34 0.63 A
300.36 82-84 67.73 6.80 8.94 0.80 B
V c ,8h 22o 3n 2 58 68.85 7.06 8.92 0.59 A
314.39 178-180 69.06 7.03 8.97 0.75 B
VI c I8h 2Io 3n 2f , 76 65.12 6.57 8.44 0.51 A
332.38 192-194 64.87 6.48 8.28 0.92 B
VII C 221 122() ,N> 81 73.00 6.13 7.74 0.71 A
362.43 230-232 72.72 6.07 7.69 0.90 B
VIII c 23h 23o ,n 2f 75 70.12 5.88 7.11 0.58 A
394.45 176-178 69.96 5.88 7.01 0.87 B
IX C 24 H 26 0 4N 2 81 71.00 6.45 6.90 0.64 A
406.48 206-208 71.07 6.46 6.82 0.84 B
X c 24h 26o 4n 2 84 71.00 6.45 6.90 0,42 A
406.48 158-160 70.90 6.48 6.87 0,87 B
XI C22H220 3N2 78 73.00 6.13 7.74 0,64 A
362.43 140-142 72.65 6.08 7.72 0,94 B
XII C23H240 4N2 68 70.47 6,17 7.15 0,35 A
392.46 104-106 70.24 6.17 7.05 0,91 B
'' Solvents: A -  benzene : ethyl acetate: aceton (10 : 5 : 1), B -  butanol : acetic acid : water ( 5 : 4 :  1)
Signal multiplicities were given the following ab­
breviations: s (singlet), d (doublet), dd (double 
doublet), q (quartet), m (multiplet). Mass spectra 
(El) were measured on a 95 MATS Sigimann 
spectrometer. Elemental analyses of C, H, N were 
within ±0.4% of the theoretical values. The purity 
of the compounds was checked by thin-layer chro­
matography (TLC) performed on Merck silica gel
GF254 aluminium sheets, using the following deve­
loping systems:
A -  benzene ; ethyl acetate : acetone (1 0 :5 :1 ) ,  
B - butanol : acetic acid : water (5 : 4 : 1 ). Spots were 
detected by means of their, absorption under UV light, 
and by visualization with 0.05 mol I2 in 10 % HC1.
GENERAL PROCEDURE FOR PREPARING
3-SPIR O C Y CLO H EX A N EPY RRO LID IN E-2,5-
Synthesis, physicochemical and anticonvulsant properties... 
Table 3. ’H NMR and MS spectral data of compounds IV -X II
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No. 'H NMR 5 (ppm)/ CDCI, EIMS m/z (% intensity)
IV 1.28-1.86 (10H, m, cyclohexane), 2,64 (2H, s, imide),4.29 (2H, 
s,CH2), 7.07-7.11 (1H, t, NH, 7=7.15), 7.28-7.66 (5H, m, aromat.)
300 [M++ 1 ] (82), 208 (15), 180 (57), 
152 (14), 95 (13), 92 (100).
V 1.23-1.86 (10H, m, cyclohexane), 2.61 (2H, s, imide), 4.15 (2H, 
s,CH2), 4.30-4.45 (2H, d, CH2-benzyl 7=5.77), 5.92 (IH,s, NH),
7.24-7.36 (5H, m, aromat.)
314 [M++l] (27), 180 (7), 106 (100), 
92 (18)
VI 1.21-1.87 (10H, m, cyclohexane), 2.61 (2H, s, imide), 4.14 (2H, 
s,CH2), 4.38-4.40 (2H, d, CH2-benzyl, 7=5.77), 5.99 (lH,s, NH), 
6.96-7.25 (4H, m, aromat.)
332 [M++ 1 ] (26), 208 (11), 180 (17), 
124 (100), 109 (20), 95 (14).
VII 1.21-1.96 (10H, m, cyclohexane), 2.75 (2H, s, imide), 7.13-7.18, (1H, 
m, NH), 7.26-7.96 (9H, m, aromat.)
362 [M++l] (21), 270 (100), 146 
(20), 95 (4), 92 (2)
VIII 1.21-1.94 (10H, m, cyclohexane), 2.73 (2H, s, imide), 4.59-4.61 (2H, d, 
CH2-benzyl, 7=5.5Hz), 6.43 (1H, s, NH), 6.99-7.88 (8H, m, aromat.)
394 [M++ 1 ] (100), 270 (77), 124 (7), 
95 (4)
IX 1.35-1.95 (10H, m, cyclohexane), 2.72 (2H, s, imide), 3.87 (3H, s, 
OCH,), 4.62-4.64 (2H, d, CH2-benzyl, 7=5.77Hz), 6.65-6.68 (1H, t, 
NH, 7=5.22Hz) 6.88-7.85 (8H, m, aromat.)
406 [M++ 1 ] (97), 270 (65), 136 (100), 
95 (5).
X 1.33-1.94 (10H, m, cyclohexane), 2.72 (2H, s, imide), 3.80 (3H, s, 
OCH,), 4.56-4.58 (2H, d, CH2-benzyl, 7=5.5Hz), 6.33-6.35 (1H, t, NH, 
7=5.55Hz) 6.85-7.88 (8H, m, aromat.)
406 [M++l] (100), 270 (51), 136 (19), 
95 (2)
XI 1.57-2.25 (8H, m, cyclopentane), 2.75 (2H, s, imide), 4.63^1.65, (2H, d, 
CHr-benzyl, 7=5.77Hz), 6.45-6.48 (1H, t, NH, 7=4.95Hz) 7.27-7.88 
(8H, m, aromat.)
362 [M++l] (100), 256 (56), 105 (17), 
90 (12), 81 (15)
XII 1.75-2.27 (8H, m, cyclopentane), 2.75 (2H, s, imide), 3.79 (3H, s, 
OCH,), 4.56^1.57, (2H, d, CH2-benzyl, 7=5.77Hz), 6.36-6.39 (1H, t, 
NH, 7=4.95Hz) 6.85-7.87 (8H, m, aromat.)
392 [M++l] (100), 256 (60), 240 (4), 
136 (19), 121 (14), 81 (12)
D IO N E -1- ACETIC ACID [I], 3-SPIR O C Y C- 
L O H E X A N E P Y R R O L ID IN E -2 ,5-D IO N E -1 - (4  
-CA RB O X Y ) BENZOIC ACID [II], AND 3 -  
SPIR O C Y C L O PEN T A N EPY R R O L ID IN E -2,5- 
D IO N E-1 -(4 -C  ARB OX Y) BENZOIC ACID [III],
To a suspension of 2-cyclohexane-2-carboxy 
acetic acid or 2-cyclopentane-2-carboxy acetic acid 
(0.04 mole) in 25 ml o f water 2-aminoacetic acid or
4—aminobenzoic acid (0.04 mole) were gradually 
added. The mixture was heated in an oil bath with 
simultaneous distillation of water. After complete 
removal of water, the temperature of reaction mix­
ture was raised up to 190-200°C and maintained for
1.5 h. The precipitated crude product was recrystal­
lized from 96% ethanol. Physicochemical data, 
H NV1R spectral data, yields, elemental analysis 
and Rr values are presented in Table 1.
GENERAL PROCEDURE FOR THE PRE­
PARATION OF N-BENZYLAND N-PHENYLA- 
MIDES OF 3-SPIRO-CYCLOHEXANEPYRRO- 
L ID IN E -2 ,5-D IO N E -1 -  ACETIC ACID [IV -VI],
3-SPIR O C Y CLO H EX A N EPY RRO LID IN E-2,5- 
D IO N E -1- BENZOIC ACID [VII-X] AND 
3-SPIROCYCLOPENTANEPYRROLIDINE-2,5- 
D IO N E -1- BENZOIC ACID [XI-XII],
The obtained acids [I, II, III] (0.02 mole) 
were dissolved in 20 ml of DMF, and N ,N-car- 
bonylodiimidazole (0.02 mole) was added. The 
mixture was stirred for 0.5 h at room temperature. 
Afterwards, the appropriate substituted phenyl- or 
benzyl- amine (0.02 mole) were added. After 24 
h of stirring at room temperature, the product was 
left in an ice-cold bath and was precipitated with 
cold water and then purified by crystallization from 
isopropanol. Physicochemical data, yields, elemen­
tal analysis and Rf values are presented in Table 2.
The 'H -N M R  and MS spectral data are pre­
sented in Table 3.
Pharmacology
Compounds I and IV -X II were pharmacolo­
gically pre-evaluated within the Antiepileptic Drug
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I 30 0/1 0/1 0/1 0/1 0/4 0/2 2
100 0/3 0/3 0/1 0/1 0/8 1/4
300 0/1 0/1 1/5 0/1 1/4 0/2
IV 30 0/1 0/1 O/l4 0/1 0/4 0/2 3
100 0/3 0/3 0/1 O/l4 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
V 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 1/4 0/2
VI 10 0/1 0/1 0/1 0/1 0/4 0/2 3
30 0/3 0/3 0/1 0/1 1/8 0/4
100 0/1 0/1 0/1 0/1 0/4 0/2
VII 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 1/1 1/4 0/2
V III 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
IX 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
X 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
XI 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 1/4 0/2
XII 30 0/1 0/1 0/1 0/1 0/4 0/2 3
100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 1/1 0/4 0/2
"M axim al electroshock test (number o f animals protected/ number of animals tested); h)Subculaneous pentylenetetrazole test; "Rolorod 
toxicity (number of animals exhibiting toxicity/ number of animals tested); d)The classification are as follows: 1-anticonvulsant activity at 
doses 100 mg/kg or less; 2-anticonvulsant activity at doses greater than 100 mg/kg; 3-com pound inactive at 300 mg/kg.
Response comments: 'death following tonic extension.
Development (ADD) Program, Epilepsy Branch, 
Neurological Disorders Program, National Institute 
of the Neurological and Communicative Disorders 
and Stroke (NINCDS), Bethesda, by using testing 
procedures described elsewhere (18,19). Phase 
I studies of the investigated compounds involved 
three tests: maximal electroshock (MES), subcuta­
neous metrazole (sc. MET) and a rotorod test for 
neurological toxicity (TOX). Phase I involved i. p. 
administration of the compounds as suspension in 
0.5% methylcellulose. Phase I was a qualitative 
assay involving a small number of mice (1-4) at
dose levels o f 30, 100, and 300 mg/kg. The com­
pounds were classified as the following categories: 
anticonvulsant activity at 100 mg/kg or less (class 
1), anticonvulsant activity at doses greater than 100 
mg/kg (class 2), compounds inactive at 300 mg/kg 
(class 3). The results are given in Table 4.
RESULTS
In this study, we attempted to correlate the 
anticonvulsant activity of N-phenyl and N-benzyl 
amides of 2-(3-spirocyclohexanepyrrolidine-2,5-
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Table 5. clog P  values of anticonvulsant drugs a obtained compounds [I, IV -X II)
Drugs clog P clog P compounds No. comp. Class ASP
Rufinamide 0,54 -0,05 I 2
Remacemide 2,27 1,37 IV 3
Ameltolide 2,91 1,00 V 3
Seretolide 2,99 1,16 VI 3
Cerabersat 3,25 3,13 VII 3
Harkoserid 2,51 3,08 VII 3
Carbamazepine 2,70 2.89 IX 3
Progabide 3,14 2,88 X 3
Valnoctamid 1,88 2,43 XI 3
Fenytoin 1,68 2,38 XII 3
dione) acetic acid [IV-VI], 4-(3-spirocyclohexa- 
nepyrrolidine-2,5-dione) benzoic acid [VII-X] 
and 4-(3-spirocyclopentanepyrrolidine-2,5-dione) 
ben/.oic acid LXI, XII] with their calculated clog 
P values. All the screened amides were devoid of 
anticonvulsant activity. Surprisingly enough, the 
investigated compounds [IV-XII] had their clog 
P  values in the range from 1.00 to 3.13 the values 
being comparable with clog P of potent anticonvul­
sant drugs, ranging from 0.12 to 3.25 (Table 5).
In conclusion, although a 3-spirocycloalkyl- 
pyrrolidine-2,5-dine fragment, an amide function, 
an aromatic area, and selected substituents in the 
phenyl ring are required for anticonvulsant activity, 
none of the compounds synthesized in our ex­
periment was active in the tests used.
The obtained results suggest that the anticon­
vulsant activity of the investigated by us derivati­
ves of 3-spirocycloalkylpyrrolidine-2,5-dione 
with an amide fragment separated by the methylene 
group or the phenyl ring at the nitrogen atom 
cannot be explained by their lipophilicity. We 
assume that hydrophobicity is the property not only 
responsible for anticonvulsant activity.
In the nearest future, on the basis of the 
hitherto obtained results we will synthesize new 
N-substituted amides of 3-spirocycloalkylpyrroli- 
dine-2,5-dione, in which the substitution pattern 
and the nature of substituents in the amine aromatic 
ring will be changed (fluor and mcthoxy groups by 
the methyl, chlor, or amine groups, respectively) to 
optimize the anticonvulsant activity. Our results 
will be published soon.
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